Kyle Faget Authors Article on Considerations for Mobile Health Technology Developers
28 September 2022
Foley & Lardner LLP Partner Kyle Faget authored the article, “Considerations for Mobile Health Technology Developers: Part 1,” published by pharmaphorum, about the U.S. Food and Drug Administration (FDA)’s common approach to regulating mHealth products, general wellness devices, and mobile medical applications.
Faget says, “Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to (FDA) regulation as a medical device. If so, developers must develop and execute on a regulatory strategy.”
Part 2 of this series will be devoted to clinical decision support (CDS) software.
People
Related News
17 May 2024
In the News
Foley’s IP Litigation Win Receives Shout Out in AmLaw Litigation Daily, Highlighted Across Legal Press
Foley & Lardner LLP’s recent delivery of summary judgment in a trademark and trade dress infringement case received coverage across legal press
14 May 2024
In the News
Thomas Ferrante on Interstate Health Policy Conflicts – ‘I’d definitely recommend paying attention’
Foley & Lardner LLP partner Thomas Ferrante offered insight on how a patchwork of shifting state legislation on health care issues are stretching constitutional limits
14 May 2024
In the News
Christopher Swift on China Biotech Crackdown – ‘There’ll be more self-initiated serious investigations into these kinds of transactions’
Foley & Lardner LLP partner Christopher Swift assessed the potential impact of the BIOSECURE Act – aimed at banning trade with major Chinese biotechnology firms